Applied Therapeutics, Inc. (: APLT)

Applied Therapeutics, Inc. (APLT) is a company that operates in the biopharmaceutical industry, with a focus on developing novel product candidates against validated molecular targets in indications of high unmet medical need. The company's main business activities involve the development of its pipeline of Aldose Reductase Inhibitors (ARIs), which target molecules and pathways that have a proven role in disease. These ARIs are designed using recent technological advances, and the company employs early use of biomarkers to confirm biological activity, with a focus on abbreviated regulatory pathways.

Applied Therapeutics' primary products include AT-007, AT-001, and AT-003, which are being developed for the treatment of rare metabolic diseases, diabetic cardiomyopathy, and diabetic retinopathy, respectively. The company's pipeline is led by AT-007, which is being developed for the treatment of Galactosemia and SORD Deficiency, two rare pediatric metabolic diseases. AT-007 has demonstrated significant reduction in plasma galactitol levels in both adults and children with Galactosemia, and has been shown to be safe and well-tolerated in patients with SORD Deficiency. A Marketing Authorization Application (MAA) has been submitted to the European Medicines Agency (EMA) and a New Drug Application (NDA) has been submitted to the US FDA for AT-007.

AT-001 is being developed for the treatment of diabetic cardiomyopathy, a fatal fibrosis of the heart. The compound has demonstrated a strong trend in stabilizing cardiac functional capacity in a Phase 3 registrational trial, and has been shown to be safe and well-tolerated in patients with diabetic cardiomyopathy. AT-003 is being developed for the treatment of diabetic retinopathy, a leading cause of blindness in working-age adults. The compound has demonstrated strong retinal penetrance and has been shown to be safe and well-tolerated in patients with diabetic retinopathy.

In terms of its position within the industry, APLT is a relatively small company with a market capitalization of around $500 million. However, the company has a strong pipeline of product candidates and a unique approach to drug development that sets it apart from larger pharmaceutical companies. The company's competitive advantages include its unique approach to drug development, which leverages recent technological advances to design improved drugs, and its focus on abbreviated regulatory pathways. The company's pipeline is also supported by a strong intellectual property position, which includes patents and trade secrets.

The company's customers include patients with rare metabolic diseases, diabetic cardiomyopathy, and diabetic retinopathy, as well as healthcare providers and pharmaceutical companies. APLT has entered into several license agreements with universities and research institutions, including Columbia University, University of Miami, and University of Rochester, to develop and commercialize its product candidates. These agreements provide APLT with access to proprietary technology and expertise, as well as potential future revenue streams.